Publications

Chosen filters:
Chosen filters:

1 - 5 of 5 results

Sorteren op
Search term:

Dopaminergic medication counteracts conflict adaptation in patients with Parkinson's disease Vrije Universiteit Brussel Ghent University

Wout Duthoo, Senne Braem, Femke Houtman, Nathalie Schouppe, Patrick Santens, Wim Notebaert

OBJECTIVE: We tested the role of dopamine in conflict-induced behavioral adjustments by evaluating the effect of dopaminergic medication on conflict adaptation in Parkinson's disease (PD) patients.

METHOD: Nine PD patients performed a vocal Stroop task on two separate testing occasions: once on their regular medication and once after overnight withdrawal.

RESULTS: In line with previous studies (e.g., Bonnin, Houeto, Gil, & ...

Epidemiology of major depression in Belgian parkinsonian patients Vrije Universiteit Brussel

Jean-Emile Vanderheyden, Michel Gonce, Philip Bourgeois, Patrick Cras, André Roch De Nayer, Anja Flamez, Frédéric Supiot, Anne-Françoise Donneau, Adelin Albert, Valérie Berlaimont, et al.

BACKGROUND: Epidemiological data concerning the prevalence of major depression in PD patients in Belgium is very scarce.

METHODS: A total of 1086 patients with idiopathic Parkinsons disease were included in the analysis. The neurological evaluation of the patients was made by the Hoehn and Yahr Staging of Parkinsons disease, the Unified Parkinson Disease Rating Scale (UPDRS), and the Schwab and England Activities of Daily Living. The ...

Treatments for progressing Parkinson's disease Vrije Universiteit Brussel

Alain Maertens de Noordhout, Patrick Santens, Jean-Marie Gérard, Michel Gonce, Anne Jeanjean, Anja Flamez, Barbara Pickut, Michel Van Zandijcke, Rajesh Pahwa

OBJECTIVE: A 'case scenario' study on clinical decisions in progressing Parkinson's disease (PD) was developed to complement scientific evidence with the collective judgment of a panel of experts.

METHODS: The opinions of 9 experts in movement disorders on the appropriateness of 9 common pharmacological treatments for 33 hypothetical patient profiles were compared to those of 14 general neurologists. Before rating the case scenarios, ...

Comparative pharmacological effects of lisuride and lysergic acid diethylamide revisited Ghent University

Grant C. Glatfelter, Eline Pottie, John S. Partilla, Christophe Stove, Michael H. Baumann
Lisuride is a non-psychedelic serotonin (5-HT) 2A receptor (5-HT2A) agonist and analogue of the psychedelic lysergic acid diethylamide (LSD). Lisuride also acts as an agonist at the serotonin 1A receptor (5-HT1A), a property known to counter psychedelic effects. Here, we tested whether lisuride lacks psychedelic activity due to a dual mechanism: (1) partial agonism at 5-HT2A and (2) potent agonism at 5-HT1A. The in vitro effects of lisuride, ...

Rotigotine is a potent agonist at dopamine D-1 receptors as well as at dopamine D-2 and D-3 receptors Ghent University

Martyn Wood, Vanessa Dubois, Dieter Scheller, Michel Gillard
Background and PurposeRotigotine acts as a dopamine receptor agonist with high affinity for the dopamine D-2, D-3, D-4 and D-5 receptors but with a low affinity for the dopamine D-1 receptor. We have investigated this further in radioligand binding and functional studies and compared the profile of rotigotine with that of other drugs used in the treatment of Parkinson's disease (PD). Experimental ApproachThe binding of rotigotine to human ...